6311-47-3

Usage

Uses

Used in Pharmaceutical Research and Development:
5-bromo-2-nitro-N-phenyl-aniline is utilized as a reagent in the development of pharmaceuticals and agrochemicals. Its unique chemical structure and properties contribute to the advancement of new drug formulations and therapeutic agents.
Used in Organic Synthesis:
As an intermediate in the synthesis of various organic compounds, 5-bromo-2-nitro-N-phenyl-aniline plays a crucial role in the creation of complex organic molecules, which can be used in a wide range of applications, from chemical industries to specialized research.
Used in Cancer Therapy Research:
5-bromo-2-nitro-N-phenyl-aniline has been studied for its potential anti-tumor and anti-cancer properties. It is being investigated for its possible use in cancer therapy, where it could contribute to the development of novel treatments for various types of cancer.
Used in Chemical and Medicinal Research:
5-bromo-2-nitro-N-phenyl-aniline's properties make it a valuable tool for researchers in the fields of chemistry and medicine. It aids in understanding the mechanisms of chemical reactions and the development of new therapeutic approaches, particularly in the context of cancer treatment.

InChI:InChI=1/C12H9BrN2O2/c13-9-6-7-12(15(16)17)11(8-9)14-10-4-2-1-3-5-10/h1-8,14H

Upstream product

• 610-38-8 4-bromo-1,2-dinitrobenzene 
• 62-53-3 aniline 
• 51686-78-3 2,4-dibromonitrobenzene 
• 321-23-3 4-bromo-2-fluoronitrobenzene 

Downstream Products

• 1116091-02-1 C₂₀H₁₄N₂O₂ 
• 1616096-79-7 1-(3,4-dihydroisoquinolin-2(1H)-yl)-3-(3-(1-phenyl-1H-benzo[d]imidazol-6-yl)phenoxy)propan-2-ol 
• 1396778-99-6 (2,6-dimethyl-4-(4-nitro-3-(phenylamino)phenyl)piperazin-1-yl)(phenyl)methanone 
• 1396780-27-0 5-(3,5-dimethylpiperazin-1-yl)-2-nitro-N-phenylaniline 
• 343952-87-4 5-bromo-N¹-phenylbenzene-1,2-diamine 

Relevant academic research and scientific papers

Benzimidazolone derivatives organic light emitting compound and organic electroluminescent device including the same

Provided is a benzo imidazolone derivative organic electroluminescent compound represented by chemical formula a. Chemical Formula a. The benzo imidazolone derivative organic light emitting compound is suitable for inclusion in an organic electroluminescent device. Both electrochemical stability and thermal stability can be satisfactorily met.

KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

Disclosed are kinase inhibitor compounds having the following structure: (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3,R4, R5, R6, N-Ar, X, Y, Z, and AA are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE

Disclosed herein are kinase inhibitor compounds having structure (I), or a stereoisomer, pharmaceutically acceptable salt, oxide, or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, X, Y, Z, and (AA) are as defined herein. Also disclosed are compositions containing the kinase inhibitor compounds, methods of inhibiting activity of a kinase in a cell, methods of increasing cell proliferation in a population of pancreatic beta cells, methods of treating a subject for a condition associated with insufficient insulin secretion, and methods of treating a subject for a neurological disorder.

Bipolar material and organic light emitting diode element

The invention provides a bipolar material in which carbazole is linked with benzimidazole carbon nitrogen and an organic light emitting diode element utilizing the bipolar material. The organic lightemitting diode element comprises a substrate, a first conducting layer, an electric hole transfer layer, a light emitting layer, an electronic transfer layer and a second conducting layer, wherein thefirst conducting layer is arranged on the substrate; the electric hole transfer layer is arranged on the first conducting layer; the light emitting layer is arranged on the electric hole transfer layer and comprises the bipolar material in which carbazole is linked with benzimidazole carbon nitrogen; and the electronic transfer layer is arranged on the electronic transfer layer.

Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design, synthesis and preliminary anticancer activity studies of 3-substituted-5-(phenylamino) indolone derivatives

The dysfunction and mutual compensatory activation of RAF-MEK-ERK and PI3K-PDK1-AKT pathways have been demonstrated as the hallmarks in several primary and recurrent cancers. The strategy of concurrent blocking of these two pathways shows clinical merits on effective cancer therapy, such as combinatory treatments and dual-pathway inhibitors. Herein, we report a novel prototype of dual-pathway inhibitors by means of merging the core structural scaffolds of a MEK1 inhibitor and a PDK1 inhibitor. A library of 43 compounds that categorized into three series (Series I–III) was synthesized and tested for antitumor activity in lung cancer cells. The results from structure-activity relationship (SAR) analysis showed the following order of antitumor activity that 3-hydroxy-5-(phenylamino) indolone (Series III) > 3-alkenyl-5-(phenylamino) indolone (Series I) > 3-alkyl-5-(phenylamino) indolone (Series II). A lead compound 9za in Series III showed most potent antitumor activity with IC50 value of 1.8 ± 0.8 μM in A549 cells. Moreover, antitumor mechanism study demonstrated that 9za exerted significant apoptotic effect, and cellular signal pathway analysis revealed the potent blockage of phosphorylation levels of ERK and AKT in RAF-MEK-ERK and PI3K-PDK1-AKT pathways, respectively. The results reported here provide robust experimental basis for the discovery and optimization of dual pathway agents for anti-lung cancer therapy.

SMALL MOLECULE INHIBITORS OF DYRK1A AND USES THEREOF

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a benzimidazole or imidazopyridine structure which function as inhibitors of DYRK1A protein, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, glioblastoma, autoimmune diseases, inflammatory disorders (e.g., airway inflammation), and other diseases.

PAN-GENOMIC INHIBITORS OF NS5A PROTEIN ENCODED BY HCV, PHARMACEUTICAL COMPOSITIONS, INTERMEDIATES FOR INHIBITOR SYNTHESIS, AND THEIR SYNTHESIS AND APPLICATION METHODS.

Compound represented by formula 1 : or a pharmaceutically acceptable salt, a hydrate, a crystalline form, or a stereoisomer thereof, wherein: where R11 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C6 cycloalkyl, or an optionally substituted C1-C6 alkyloxy, and arrows (1-C4alkyl; R3 is an optionally substituted aryl, an optionally substituted aryloxy, an optionally substituted arylsulfanyl, an optionally substituted arylamino, or an optionally substituted nitrogen hetaryl; where R41 is an optionally substituted C1-C6 alkyl, an optionally substituted C3-C6 cycloalkyl, or an optionally substituted C1-C6 alkyloxy; X is buta-1,3-diynylene or 1,4-phenylene; arrows (— ) indicate the position of substituents attachment.

Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof

The present invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In another aspect, the invention provides for a method for treating a disease condition associated with PI3-kinase α and/or mTOR in a subject. In yet another aspect, a method of inhibiting phosphorylation of both Akt (S473) and Akt (T308) in a cell is set forth.

LUMINESCENT DIAZA- MONOAZA- AND BENZIMIDAZOLE METAL CARBENE COMPLEXES FOR USE IN ELECTRONIC DEVICES SUCH AS OLEDS

A cyclometallated Ir complex comprising one, two or three ligands of formula (I) or (I') substituted at the R5 and R7 position; an organic electronic device comprising at least one inventive cyclometallated Ir complex; alight-emitting layer comprising at least one inventive cy-clometallated Ir complex; the use of the inventive cyclometallated Ir complexin an OLED; an apparatus selected from the group consisting of stationary visual display units, mobile visual display units, illumination units, units in items of clothing, units in handbags, units in accessories, units in furniture and units in wallpaper, comprising the organic electronic device; and a process for preparing a the inventive cyclometallated Ir complex.

METAL COMPLEXES, COMPRISING CARBENE LIGANDS HAVING AN O-SUBSTITUTED NON-CYCLOMETALATED ARYL GROUP AND THEIR USE IN ORGANIC LIGHT EMITTING DIODES

Cyclometallated Ir complex comprising three N,N diaryl substituted carbene ligands, bearing substituents in the 2 position of the non-cyclometallated aryl ring;an organic electronic device, preferably an organic light-emitting diode (OLED), comprising at least one cyclometallated Ir complexas described above, a light-emitting layer comprising said cyclometallated Ir complex preferably as emitter material, preferably in combination with at least one host material, use of said cyclometallated Ir complex in an OLED and an apparatus selected from the group consisting of stationary visual display units, mobile visualdisplay units, illumination units, units in items of clothing, units in handbags, units in accessoires, units in furniture and units in wallpaper comprising said organic electronic device, preferably said OLED, or said light-emitting layer. The present invention further relates to a process for the preparation of said cyclometallated Ir complex.